Currently, researchers are investigating the clinical efficacy of Pembrolizumab (Keytruda) as a monotherapy or in combination therapies for MM patients who have not responded to anti-BCMA CAR-T therapy (Chung et al., 2022). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.